Boston Scientific Corp $ 43.21 -0.36 (-0.83%)
On watch
Volume:
4,021,070
Avg Vol (1m):
6,761,765
Market Cap $:
60.23 Bil
Enterprise Value $:
70.84 Bil
P/E (TTM):
56.12
P/B:
6.21
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.03 | ||
| Equity-to-Asset | 0.36 | ||
| Debt-to-Equity | 1.12 | ||
| Debt-to-EBITDA | 5.43 | ||
| Interest Coverage | 4.8 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 2.37 | ||
| Beneish M-Score | -2.31 | ||
| WACC vs ROIC | |||
Profitability Rank | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 16.5 | ||
| Net Margin % | 10.49 | ||
| ROE % | 12.01 | ||
| ROA % | 4.69 | ||
| ROC (Joel Greenblatt) % | 36.14 | ||
| 3-Year Revenue Growth Rate | 7.9 | ||
| 3-Year EBITDA Growth Rate | 82.5 |
Valuation Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 56.12 | ||
| Forward PE Ratio | 24.33 | ||
| PE Ratio without NRI | 56.12 | ||
| Price-to-Owner-Earnings | 41.31 | ||
| PB Ratio | 6.21 | ||
| PS Ratio | 5.86 | ||
| Price-to-Free-Cash-Flow | 77.86 | ||
| Price-to-Operating-Cash-Flow | 52.38 | ||
| EV-to-EBIT | 52.63 | ||
| EV-to-EBITDA | 35.3 | ||
| EV-to-Revenue | 6.82 | ||
| PEG Ratio | 1.49 | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 0.77 | ||
| Days Inventory | 155.9 | ||
| Days Sales Outstanding | 63.08 | ||
| Days Payable | 62.42 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 4.02 | ||
| Price-to-Median-PS-Value | 2.42 | ||
| Earnings Yield (Greenblatt) % | 1.9 | ||
| Forward Rate of Return (Yacktman) % | -16.22 |